We are live on ! Find out more
SPRY icon

ARS Pharmaceuticals
SPRY

68 hedge funds and large institutions have $1.21B invested in ARS Pharmaceuticals in 2021 Q1 according to their latest regulatory filings, with 29 funds opening new positions, 12 increasing their positions, 12 reducing their positions, and 23 closing their positions.

New
Increased
Maintained
Reduced
Closed

26% more first-time investments, than exits

New positions opened: 29 | Existing positions closed: 23

10% more funds holding

Funds holding: 62 → 68 (+6)

9.33% more ownership

Funds ownership: 70.26% → 79.6% (+9.3%)

7% more capital invested

Capital invested by funds: $1.13B → $1.21B (+$79.1M)

0% more repeat investments, than reductions

Existing positions increased: 12 | Existing positions reduced: 12

25% less funds holding in top 10

Funds holding in top 10: 4 → 3 (-1)

Holders
68
Holders Change
+6
Holders Change %
+9.68%
% of All Funds
1.19%
Holding in Top 10
3
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-25%
% of All Funds
0.05%
New
29
Increased
12
Reduced
12
Closed
23
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Fidelity Investments
Fidelity Investments
Massachusetts
+$65.5M
2
Vanguard Group
Vanguard Group
Pennsylvania
+$49M
3
BlackRock
BlackRock
New York
+$39.2M
4
Point72 Asset Management
Point72 Asset Management
Connecticut
+$13.6M
5
D.E. Shaw & Co
D.E. Shaw & Co
New York
+$9.72M

Top Sellers

Rank Fund Capital Flow
1
NCM
Nantahala Capital Management
Connecticut
-$10.1M
2
LGM
Logos Global Management
California
-$8.28M
3
Citadel Advisors
Citadel Advisors
Florida
-$6.4M
4
Millennium Management
Millennium Management
New York
-$6.12M
5
Goldman Sachs
Goldman Sachs
New York
-$4.07M
Name Holding Trade Value Shares
Change 		Change in
Stake
SCM
26
Soleus Capital Management
Connecticut
$4.24M -$500K -10,570 -10%
CC
27
Commodore Capital
New York
$4.24M – – –
VA
28
VR Adviser
New York
$3.71M -$3.08M -65,000 -43%
Charles Schwab
29
Charles Schwab
California
$3.68M +$3.99M +84,413 New
PAMU
30
Pictet Asset Management (UK)
United Kingdom
$3.42M -$2.21M -46,652 -37%
N
31
Nuveen
North Carolina
$2.19M +$2.38M +50,250 New
Millennium Management
32
Millennium Management
New York
$1.6M -$6.12M -129,287 -78%
Bank of New York Mellon
33
Bank of New York Mellon
New York
$1.52M +$1.65M +34,812 New
Victory Capital Management
34
Victory Capital Management
Texas
$1.35M -$559K -11,810 -28%
JP Morgan Chase
35
JP Morgan Chase
New York
$1.24M +$1.34M +28,350 New
Bank Julius Baer & Co
36
Bank Julius Baer & Co
Switzerland
$1.23M +$1.33M +28,187 New
Bank of America
37
Bank of America
North Carolina
$1.17M +$1.27M +26,759 New
Alyeska Investment Group
38
Alyeska Investment Group
Illinois
$1.09M – – –
CCM
39
CAAS Capital Management
New York
$1.09M – – –
BOTOTLSJU
40
Board of Trustees of The Leland Stanford Junior University
California
$949K – – –
California State Teachers Retirement System (CalSTRS)
41
California State Teachers Retirement System (CalSTRS)
California
$835K +$905K +19,132 New
Janney Montgomery Scott
42
Janney Montgomery Scott
Pennsylvania
$692K +$232K +4,903 +45%
HS
43
HighVista Strategies
Massachusetts
$614K +$666K +14,067 New
RhumbLine Advisers
44
RhumbLine Advisers
Massachusetts
$575K +$624K +13,189 New
Ohio Public Employees Retirement System (OPERS)
45
Ohio Public Employees Retirement System (OPERS)
Ohio
$545K +$579K +12,232 +4,893%
Deutsche Bank
46
Deutsche Bank
Germany
$538K +$347K +7,330 +147%
ZP
47
Zimmer Partners
New York
$436K – – –
EMG
48
ETF Managers Group
New Jersey
$435K +$508K +10,726 New
New York State Common Retirement Fund
49
New York State Common Retirement Fund
New York
$336K +$364K +7,700 New
Manulife (Manufacturers Life Insurance)
50
Manulife (Manufacturers Life Insurance)
Ontario, Canada
$306K +$332K +7,018 New
1
2
3 4

SPRY Hedge Fund Activity: Q1 2021 in Review

68 of the 5,695 institutional investors tracked by Wall St. Rank reported a position in ARS Pharmaceuticals (SPRY) for Q1 2021, worth a combined $1.21B — up 7% from $1.13B a quarter earlier.

Buyers outnumbered sellers: 29 funds opened new SPRY positions and 23 closed out — a net gain of 6 holders — while 12 added to existing stakes and 12 trimmed.

The largest buyer was Fidelity Investments, adding an estimated $65.5M. The largest seller was Nantahala Capital Management, cutting an estimated $10.1M.

  • 68 institutional investors held ARS Pharmaceuticals (SPRY) as of Q1 2021, up from 62 in Q4 2020.
  • Funds reported $1.21B of ARS Pharmaceuticals stock for Q1 2021, up 7% quarter-over-quarter.
  • 29 funds opened new ARS Pharmaceuticals positions in Q1 2021 and 23 closed out, a net change of +6 holders.
  • The largest ARS Pharmaceuticals buyer in Q1 2021 was Fidelity Investments, an estimated $65.5M added.
  • The largest ARS Pharmaceuticals seller in Q1 2021 was Nantahala Capital Management, an estimated $10.1M sold.

Based on aggregated 13F filings for Q1 2021.